Since the earliest days of biotech, the UK and the USA have worked together to move science forward and build globally competitive companies.  James Watson (US) and Francis Crick (UK) worked together to solve the structure of the molecule that underpins the industry. The two technologies on which…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

Dr. Benjamin Cowen is the CEO of ImmunoMet, a clinical stage biotech company developing anti-tumor and immune-metabolism therapies. Holding both a PhD and an MBA, Cowen has worked across the spectrum of companies, including large pharma, mid-sized pharma and small venture-backed companies and his…

As a new college graduate in the early 80’s, Shawn Tomasello knew one thing for sure. She wanted a career in an industry that would constantly change; one that would keep her on her toes; allow her to always be learning.  At a career fair during her senior year, she discovered Pfizer Laboratories…

As more biotechnology executives begin to focus on strategies to diversify their boards to avoid groupthink and strengthen corporate governance, an emerging consensus is forming that initial public offerings are a key gateway to assembling higher-performing leadership teams. That was the unanimous…

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in…

This year marked the first time BIO’s Start-Up Stadium was part of the BIO World Congress on Industrial Biotechnology and Agtech. The Shark Tank-style forum provided innovators across industrial biotech and agtech unparalleled access to key members of the investment community, venture philanthropy…

In a few short months BIO will be hosting the BIO Investor Forum (#BIF19) for the 17th time. The event’s long history is testament to the continued appetite for partnerships, collaborations and investment in the exciting world of early stage biotech companies on the cusp of medical breakthroughs…

    On Tuesday morning at the 2019 BIO International Convention, COWEN CEO Jeffrey Solomon sat down for a fireside chat with Ovid Therapeutics CEO (and newly-elected BIO Chair) Dr. Jeremy Levin.   Levin introduced Solomon as a long-time passionate advocate for ensuring that small…

The past year has been a transformative one for the life sciences. Despite being faced with uncertainties around cost and pricing, pressure from an Administration threatening price controls and facing a new Congress next year, the industry continued to move forward on the innovation front. With…